Peter Keane

The study shows that RUNX1-ETO levels determine endothelial reprogramming and hematopoietic cell growth in AML by altering the balance between these processes.

The paper identifies chromatin priming elements that activate before gene expression during hematopoietic differentiation and shows their role in developmental timing.

The paper identifies thousands of cell stage-specific enhancers that drive hematopoietic specification by responding to cytokine signals and transcription factors.

The paper shows that different RUNX1 mutations alter gene regulatory networks and chromatin programming, leading to distinct hematopoietic differentiation trajectories and disease phenotypes.